Vandebroek Sophie V. 4

What Happened

• Sophie Vandebroek, a director of IDEXX Laboratories (IDXX), reported the conversion/exercise of 257 restricted stock units into 257 shares on May 7, 2026. The filing lists the acquired shares at $0.00 (reflecting RSU settlement), and a corresponding derivative disposition of 257 shares is also reported the same day.
• The filing reports $0 value for the acquired shares (standard when RSUs vest and convert to common stock as recorded on the Form 4).

Key Details

• Transaction date: May 7, 2026; Form 4 filed May 11, 2026 (within the normal reporting window).
• Reported transactions: M (exercise/conversion of derivative) — 257 shares acquired @ $0.00; a matching derivative disposition of 257 shares shown with price N/A.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: F1 states each restricted stock unit vested in one installment on May 7, 2026 and represents the right to one share of common stock.

Context

• The M code reflects conversion/exercise of a derivative (here, vested RSUs). The reported $0.00 acquisition price is typical for RSU vesting entries on Form 4s; the matching disposition is commonly used in filings for transfers or withholdings related to vesting but the filing does not detail the reason for the disposition.
• This is not a purchase or sale in the open market by the insider; it documents the vesting/settlement of an equity award.